The State of Ohio COVID-19 Dashboard displays the most recent preliminary data reported to the Ohio Department of Health (ODH) about cases, hospitalizations and deaths in Ohio by selected demographics and county of residence. Click here for the most up to date information.
Bivalent mRNA vaccines
The number of bivalent doses varies by age, vaccine, previous COVID-19 vaccines received, and the presence of moderate or severe immune compromise.
For people who are not moderately or severely immunocompromised:
For people who are moderately or severely immunocompromised:
Novavax COVID-19 Vaccine
People ages 12 years an older who previously received 1 or 2 monovalent Novavax COVID-19 primary series dose(s) are recommended to receive 1 bivalent mRNA vaccine dose. The monovalent Novavax COVID-19 Vaccine remains authorized for use as a 2-dose primary series and as a booster dose in certain limited situations.
Janssen COVID-19 Vaccine (Not Available)
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated | Interval between doses* | ||
---|---|---|---|---|---|
Unvaccinated | Moderna ___or___ Pfizer BioNTech† | 2 | Dose 1 and Dose 2: 4–8 weeks | ||
3 | Dose 1 and Dose 2: 3–8 weeks Dose 2 and dose 3: At least 8 weeks | ||||
1 dose monovalent Moderna | Moderna | 1 | 4-8 weeks after monovalent dose | ||
2 doses monovalent Moderna | Moderna | 1 | At least 8 weeks after last monovalent dose | ||
2 doses monovalent Moderna and 1 dose bivalent Moderna | NA; previously received 1 bivalent vaccine dose | NA | NA | ||
1 dose monovalent Pfizer-BioNTech | Pfizer BioNTech† | 2 | Dose 1: 3–8 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks | ||
2 doses monovalent Pfizer-BioNTech | Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
3 doses monovalent Pfizer-BioNTech | Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech | NA; previously received 1 bivalent vaccine dose | NA | NA |
Age 5 years
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated | Interval between doses* | ||
---|---|---|---|---|---|
Unvaccinated | Moderna‡ ___or___ Pfizer BioNTech | 2 | Dose 1 and Dose 2: 4–8 weeks | ||
1 | |||||
1 dose monovalent Moderna | Moderna ___or___ Pfizer BioNTech | 1 | 4–8 weeks after monovalent dose | ||
1 | At least 8 weeks after monovalent dose | ||||
2 doses monovalent Moderna | Moderna ___or___ Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
2 doses monovalent Moderna and 1 dose bivalent mRNA | NA; previously received 1 bivalent vaccine dose | NA | NA | ||
1 or more doses monovalent Pfizer-BioNTech | Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech | NA; previously received 1 bivalent vaccine dose | NA | NA | ||
Ever received 1 dose bivalent Pfizer-BioNTech (regardless of monovalent vaccine history) | NA; previously received 1 bivalent vaccine dose | NA | NA |
Ages 6–11 years
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated | Interval between doses* | ||
---|---|---|---|---|---|
Unvaccinated | Moderna ___or___ Pfizer BioNTech | 1 | — | ||
1 | — | ||||
1 or more doses monovalent mRNA (no doses bivalent mRNA) | Moderna ___or___ Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
2 or more doses monovalent mRNA and 1 dose bivalent mRNA | NA; previously received 1 bivalent vaccine dose | NA | NA | ||
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history) | NA; previously received 1 bivalent vaccine dose | NA | NA |
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated | Interval between doses* | ||
---|---|---|---|---|---|
Unvaccinated | Moderna ___or___ Pfizer BioNTech | 1 | — | ||
1 | — | ||||
1 or more doses monovalent mRNA (no doses bivalent mRNA) | Moderna ___or___ Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
Ever received 1 dose bivalent mRNA (regardless of monovalent vaccine history) | NA; previously received 1 bivalent vaccine dose | NA | NA |
Novavax COVID-19 Vaccine
People ages 12 years and older who previously received 1 or more doses of Novavax COVID-19 Vaccine are recommended to receive 1 bivalent mRNA vaccine dose.
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated | Interval between doses | ||
---|---|---|---|---|---|
1 or more doses of Novavax vaccine | Moderna ___or___ Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose |
Ages 6 months–4 years
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated* | Interval between doses | ||
---|---|---|---|---|---|
Unvaccinated | Moderna ___or___ Pfizer BioNTech† | 3 | Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks | ||
3 | Dose 1 and Dose 2: 3 weeks Dose 2 and dose 3: At least 8 weeks | ||||
1 dose monovalent Moderna | Moderna | 2 | Dose 1: 4 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Moderna | Moderna | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Moderna | Moderna | 1 | At least 8 weeks after last monovalent dose | ||
3 doses monovalent Moderna and 1 dose bivalent Moderna | — | See footnote | — | ||
1 dose monovalent Pfizer-BioNTech | Pfizer-BioNTech† | 2 | Dose 1: 3 weeks after monovalent dose Dose 1 and Dose 2: At least 8 weeks | ||
2 doses monovalent Pfizer-BioNTech | Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
3 doses monovalent Pfizer-BioNTech | Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
2 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech | — | See footnote | — | ||
3 doses of monovalent Pfizer-BioNTech and 1 bivalent Pfizer-BioNTech dose | — | See footnote | — |
Ages 5 years
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated* | Interval between doses | ||
---|---|---|---|---|---|
Unvaccinated | Moderna† ___or___ Pfizer BioNTech | 3 | Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks | ||
3 | Dose 1 and Dose 2: 3 weeks Dose 2 and dose 3: At least 4 weeks | ||||
1 dose monovalent Moderna | Moderna† | 2 | Dose 1: 4 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Moderna | Moderna† | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Moderna | Moderna ___or___ Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
3 doses monovalent Moderna and 1 dose bivalent mRNA | — | See footnote | — | ||
1 dose monovalent Pfizer-BioNTech | Pfizer-BioNTech | 2 | Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Pfizer-BioNTech | Pfizer-BioNTech | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Pfizer-BioNTech | Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent Pfizer-BioNTech | — | See footnote | — |
*People age 5 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of a bivalent mRNA vaccine at least 2 months following the last recommended bivalent mRNA COVID-19 vaccine dose. Further additional bivalent dose(s) may be administered, informed by the clinical judgement of a healthcare provider and personal preference and circumstances. Any further additional doses should be administered at least 2 months after the last COVID-19 vaccine dose. People in this age group who previously received a dose(s) of Pfizer-BioNTech vaccine are authorized to receive only Pfizer-BioNTech vaccine. Recipients who previously received Moderna vaccine are authorized to receive either bivalent mRNA vaccine.
Ages 6-11 years
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated* | Interval between doses | ||
---|---|---|---|---|---|
Unvaccinated | Moderna† ___or___ Pfizer-BioNTech‡ | 3 | Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks | ||
3 | Dose 1 and Dose 2: 3 weeks Dose 2 and dose 3: At least 4 weeks | ||||
1 dose monovalent Moderna | Moderna† | 2 | Dose 1: 4 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Moderna | Moderna† | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Moderna | Moderna ___or___ Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
3 doses monovalent Moderna and 1 dose bivalent mRNA | — | See footnote | — | ||
1 dose monovalent Pfizer-BioNTech | Pfizer-BioNTech‡ | 2 | Dose 1: 3 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Pfizer-BioNTech | Pfizer-BioNTech‡ | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Pfizer-BioNTech | Moderna ___or___ Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNA | — | See footnote | — |
*People ages 6–11 years who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine. at least 2 months following the last recommended bivalent COVID-19 vaccine dose.
Ages 12 years and older
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated* | Interval between doses | ||
---|---|---|---|---|---|
Unvaccinated | Moderna† ___or___ Pfizer BioNTech‡ | 3 | Dose 1 and Dose 2: 4 weeks Dose 2 and Dose 3: At least 4 weeks | ||
3 | Dose 1 and Dose 2: 3 weeks Dose 2 and dose 3: At least 4 weeks | ||||
1 dose monovalent Moderna | Moderna† | 2 | Dose 1: 4 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Moderna | Moderna† | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Moderna | Moderna ___or___ Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
3 doses monovalent Moderna and 1 dose bivalent mRNA | — | See footnote | — | ||
1 dose monovalent Pfizer-BioNTech | Pfizer-BioNTech‡ | 2 | Dose 1: 3 weeks after monovalent dose Dose 1 and Dose 2: At least 4 weeks | ||
2 doses monovalent Pfizer | Pfizer-BioNTech‡ | 1 | At least 4 weeks after last monovalent dose | ||
3 doses monovalent Pfizer-BioNTech | Moderna ___or___ Pfizer-BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose | ||||
3 doses monovalent Pfizer-BioNTech and 1 dose bivalent mRNA | — | See footnote | — |
*People ages 12 years and older who are moderately or severely immunocompromised have the option to receive 1 additional dose of Moderna COVID-19 Vaccine. at least 2 months following the last recommended bivalent COVID-19 vaccine dose.
Novavax COVID-19 Vaccine
People ages 12 years and older who previously received 1 or more doses of Novavax COVID-19 Vaccine are recommended to receive 1 bivalent mRNA vaccine dose.
COVID-19 vaccination history | Bivalent vaccine | Number of bivalent doses indicated* | Interval between doses | ||
---|---|---|---|---|---|
1 or 2 doses of Novavax vaccine | Moderna ___or___ Pfizer BioNTech | 1 | At least 8 weeks after last monovalent dose | ||
1 | At least 8 weeks after last monovalent dose |
**Talk to your doctor to see if you can take Motrin or Tylenol after injections. It is not recommended to take these meds before injection. (CDC)
**After injection, exercise arm to work out soreness, apply clean, cool washcloth to site and drink plenty of water. (CDC)
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/prepare-for-vaccination.html
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html
https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html
Meigs County Health Department
Hopewell Health Pomeroy Dental and Primary Health Care Clinic
Swisher and Lohse
Fruth Pharmacy
Fruth Pharmacy (Powell’s Food Fair)
Monday- Friday
8:00AM – 4:00PM
Contact Us
Meigs County Ohio Health Department
112 E Memorial Drive Suite A Pomeroy, OH 45769
Email: courtney.midkiff@meigs-health.com
Phone: 740-992-6626
Fax: 740-992-0836
Powered By Local Impact